Description
Dapagliflozin is the first SGLT2 inhibitor approved by U.S. Food and Drug Administration(FDA) for chronic kidney disease treatment regardless of diabetes status.
Dapagliflozin is in a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It lowers blood sugar by causing the kidneys to get rid of more glucose in the urine
Dapagliflozin 10 mg
To Reduce the risk of :
- Kidney function decline
- Kidney failure
- Cardiovascular death & Hospitalization for heart failure with chronic kidney disease.
10mg BD
Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) trial to assess the long term efficacy and safety of the SGLT2 inhibitor dapagliflozin in patients with chronic kidney disease, with or without type 2 diabetes.
- The DAPA-CKD trial shows that the SGLT2 inhibitor improves renal and CV outcomes, and that it reduces mortality
- Patients with chronic kidney disease, regardless of the presence or absence of diabetes, the risk of a composite of a sustained decline in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes was significantly lower with dapagliflozin than with placebo.
- In patients with chronic kidney disease with and without type 2 diabetes, dapagliflozin significantly reduced albuminuria